Bearing Point Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.43M Buy
7,288
+113
+2% +$133K 1.09% 29
2026
Q2
$8.61M Buy
7,175
+4,400
+159% +$4.5M 1.16% 27
2026
Q1
$2.55M Sell
2,775
-2
-0.1% -$2.03K 0.4% 66
2025
Q4
$2.98M Buy
2,777
+103
+4% +$98.5K 0.47% 64
2025
Q3
$2.04M Sell
2,674
-253
-9% -$188K 0.35% 67
2025
Q2
$2.28M Buy
2,927
+204
+7% +$159K 0.42% 64
2025
Q1
$2.25M Buy
2,723
+237
+10% +$197K 0.48% 63
2024
Q4
$1.92M Buy
+2,486
New +$2.06M 0.4% 65

Other funds holding LLY

Bearing Point Capital's LLY Position: Q3 2026 in Review

Bearing Point Capital increased its Eli Lilly (LLY) stake by 1.6% in Q3 2026, buying an estimated $133K and bringing the position to 7,288 shares worth $8.43M. The position accounts for 1.09% of the portfolio, ranked #29.

Bearing Point Capital first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.61M in Q2 2026. 4,599 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Bearing Point Capital held 7,288 shares of Eli Lilly worth $8.43M as of Q3 2026.
  • Bearing Point Capital bought 113 Eli Lilly shares in Q3 2026, an estimated $133K.
  • Eli Lilly made up 1.09% of Bearing Point Capital's portfolio in Q3 2026, its #29 holding.
  • Bearing Point Capital first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • Bearing Point Capital's Eli Lilly position peaked at $8.61M in Q2 2026.
  • 4,599 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Bearing Point Capital's 13F filing for Q3 2026, filed 13 Nov 2026.